Driven by patient preference and encouraged by Medicare part D reimbursement, oral chemotherapies comprise nearly half of all new chemotherapy drugs in development. Patients find oral chemotherapies desirable because of the perceived convenience, autonomy, and decreased adverse effects from invasive treatments, but oral regimens are not always simple or free from toxicities.
Under the current system, medications cannot be sold in the United States until the FDA’s Center for Drug Evaluation and Research (CDER) grants approval. CDER’s approval assures consumers that prescription medications are not only safe but also effective for their intended use. Although this works to prevent misleading, harmful, or ineffective drugs from reaching patients, many critics argue that the process is bureaucratic and slows the arrival of potentially lifesaving drugs from reaching the bedside. A need to meet the demand for faster approval while ensuring safety and efficacy has resulted in several innovative review processes.
The drug shortage has caused treatment delays, compromises, and unknown clinical outcomes for patients. Some oncologists have had to create triage systems to treat the patients who are most likely to be cured. Pharmacists, oncologists, and anesthesiologists are frustrated with drug shortages and efforts to treat patients without critical drugs. Learn why this is happening and what’s being done about it.
In the animated picture Ratatouille, Remy was inspired by the slogan “Anyone Can Cook.” While not everyone can write manuscripts, in many ways, writing for publication is similar to cooking.
Even if the term is unfamiliar, odds are, nanotechnology is already a part of your everyday life. You may be using a nano product when applying sunscreen, disinfecting the floor, curling your hair, or opening a fast-food container. Nanotechnology is being studied, and in many cases implemented, in fields ranging from electronics and information technology to magnetics and optics, materials development, and biosciences.